21:57 , Jun 27, 2019 |  BC Innovations  |  Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

As in vivo gene therapies continue notching approvals for rare monogenic diseases, the next frontier for the modality will be in treating complex indications without obvious genetic drivers. At least seven companies have clinical or...
21:51 , Feb 22, 2019 |  BioCentury  |  Emerging Company Profile

Gyroscope complements dry AMD

Gyroscope Therapeutics Ltd.’s complement-targeting gene therapy for dry age-related macular degeneration could have an edge over competing therapies that are dosed chronically or target complement downstream of its key immune mediators. On Feb. 19, Gyroscope...
08:00 , Jan 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CD59; complement C5b-9 membrane attack complex (MAC)

Neurology INDICATION: Sleep apnea Cell culture and patient-derived cell studies suggest statins could help treat vascular damage associated with obstructive sleep apnea (OSA). Intracellular levels of CD59 were higher in vascular endothelial cells from patients...
08:00 , Dec 10, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: V-set and immunoglobulin domain containing 4 (VSIG4); CD59; complement C5b-9 membrane attack complex (MAC)

Inflammation INDICATION: Shock / trauma In vitro and mouse studies suggest a VSIG4- CD59 fusion protein could help treat traumatic brain injury (TBI). In vitro, dimers of the VSIG4-CD59 fusion protein bound complement 3b (C3b)...
07:00 , Sep 11, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Hepatic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hepatic disease Hepatic disease Complement receptor 2 (CR2); CD59; complement C5b-9 membrane attack complex (MAC) Mouse studies suggest a CR2-CD59 fusion protein could help treat liver...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Company News

Corgenix Medical Corp., Mellitus deal

Corgenix will develop a research test kit to measure glycated CD59 for use in Mellitus’ in vitro diagnostic for gestational diabetes mellitus. Corgenix said that Mellitus has developed a prototype and Corgenix is responsible for...
07:00 , Oct 21, 2013 |  BioCentury  |  Emerging Company Profile

Hemera: Special sauce in AMD

Hemera Bioscience Inc. is designing its MAC-based gene therapy to help treat dry and wet age-related macular degeneration more safely than other therapies targeting the complement pathway in ocular diseases. It also may offer more...
08:00 , Dec 8, 2011 |  BC Innovations  |  Cover Story

Big MAC attack in osteoarthritis

An international research team has shown that inhibiting the complement system slows disease progression in mice with osteoarthritis, thus pointing to complement inhibitors as potential disease modifiers. 1 Although the findings offer companies developing inhibitors...
08:00 , Feb 14, 2011 |  BioCentury  |  Strategy

Alexion's expansions

Alexion Pharmaceuticals Inc. last week laid out its plans for keeping up the momentum that has resulted in a doubling of market cap in the past year, from $4.1 billion on Feb. 12, 2010, to...
07:00 , Jul 28, 2008 |  BC Week In Review  |  Company News

Arius, Roche deal

Roche will acquire antibody platform company Arius for about C$191 million (US$190.7 million) in cash. The deal includes the purchase of Arius’ common shares at C$2.44 and the purchase of issued and outstanding warrants at...